Horizon Therapeutics plc Reports Strong Third-Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Horizon Pharma (HZNP) Tops Q3 EPS by 15c, Offers Guidance
November 6, 2019 7:16 AM ESTHorizon Pharma (NASDAQ: HZNP) reported Q3 EPS of $0.64, $0.15 better than the analyst estimate of $0.49. Revenue for the quarter came in at $665.5 million versus the consensus estimate of $329.76 million.
GUIDANCE:
Horizon Pharma sees Q4 2019 revenue of $1.28-1.3 billion, versus the consensus of... More
